Why the Recce (ASX:RCE) share price is surging 8% higher today

The Recce Pharmaceuticals Ltd (ASX:RCE) share price is surging higher on Thursday following a promising update…

| More on:
jump in asx share price represented by man jumping in the air in celebration

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Recce Pharmaceuticals Ltd (ASX: RCE) share price has been a strong performer on Thursday.

In afternoon trade, the biotechnology company's shares are up 8.5% to $1.13.

Why is the Recce share price surging higher?

Investors have been bidding the Recce share price higher today following the release of a promising update.

According to the release, the company has announced positive results from a pre-clinical study investigating the Mechanism of Action (MoA) of its lead compound RECCE 327 (R327).

The company notes that R327 is a broad-spectrum synthetic anti-infective that has the potential to address the urgent global health threat posed by antibiotic resistant superbugs and emerging viral pathogens.

Recce advised that the study was performed by independent, world leaders in bacterial MOA analysis and antibiotic profiling.

What were the results?

The release explains that R327's MoA was "unlike that of any antibiotic seen before" with multiple mechanisms identified in the study. These will be presented at an upcoming World Microbe Forum in June.

In addition, the study showed that R327 was rapidly and irreversibly bactericidal against Gram-negative Escherichia coli (E. coli) bacteria, in both active and stationary phase cells. Positively, it outperformed the best in class commercial antibiotics.

Management notes that current antibiotics rarely retain bactericidal activities against non-dividing bacterial cells. However, R327 shows significant activity against both slow-growing bacteria and actively dividing cells, thereby enabling continuous treatment of infections throughout the bacterial cell life cycle.

Recce's Executive Director & Chief Scientific Officer, Michele Dilizia, commented: "The data from this study further supports the potential of RECCE 327 to provide a novel and universal way to treat harmful infections. We are excited about these highly encouraging results as they provide important insights regarding how RECCE 327 is able to work repeatedly against the same strain of bacteria and their superbug forms."

Should you invest $1,000 in Recce Pharmaceuticals Ltd right now?

Before you buy Recce Pharmaceuticals Ltd shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Recce Pharmaceuticals Ltd wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

Person pretends to types on laptop drawn in sand.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors had a rough start to the week today.

Read more »

A person in a gorilla suit leaps really high holding a banana, nearly doing the splits.
Share Gainers

Up 1,238% in a year, why is this ASX gold stock surging again on Monday?

The ASX gold stock is now well into ten-bagger range and still rising fast today.

Read more »

A happy investor sits at his desk in front of his laptop and does the mexican wave with his arms to celebrate the returns from his ASX dividend shares
Share Gainers

Why EOS, Gorilla Gold, Lendlease, and OFX shares are charging higher today

These shares are starting the week on a positive note. But why?

Read more »

A woman in a business suit sits at her desk with gold bars in each hand while she kisses one bar with her eyes closed. Her desk has another three gold bars stacked in front of her. symbolising the rising Northern Star share price
Gold

How this ASX All Ords gold stock turned $10,000 into $78,740 in just one year

The ASX All Ords gold miner has raced higher over the year. Let’s find out how.

Read more »

Ten happy friends leaping in the air outdoors.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors enjoyed a happy end to the trading week this Friday.

Read more »

A woman wearing yellow smiles and drinks coffee while on laptop.
Bank Shares

CBA shares top $170. Where to now?

Another day, another record high for CBA shares.

Read more »

Two people jump and high five above a city skyline.
Share Gainers

Why these 5 ASX 200 stocks are racing higher this week

It’s been a stellar week for these five ASX 200 stocks. But why?

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Share Gainers

Why Appen, Aspen, Catalyst Metals, and Core Lithium shares are racing higher today

Let's see why these shares are roaring higher today and ending the week on a high.

Read more »